Comparing Ionis Pharmaceuticals (NASDAQ:IONS) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider and Institutional Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%

Earnings and Valuation

This table compares Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.78	$363.05 million	($1.41)	-24.06
Ionis Pharmaceuticals	$944.00 million	4.82	-$381.39 million	($3.32)	-8.23

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ionis Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Ionis Pharmaceuticals	1	3	19	0	2.78

Lakefront Biotherapeutics American Depositary Shares currently has a consensus price target of $35.50, suggesting a potential upside of 4.63%. Ionis Pharmaceuticals has a consensus price target of $78.00, suggesting a potential upside of 185.61%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.